Attached files

file filename
EX-99.1 - PRESS RELEASE - NORTHWEST BIOTHERAPEUTICS INCv346058_ex99-1.htm

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 


 

Date Of Report (Date Of Earliest Event Reported): May 23, 2013

 


 

NORTHWEST BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)

 


 

Delaware   0-33393   94-3306718
(State Or Other Jurisdiction Of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

4800 Montgomery Lane, Suite 800, Bethesda, MD 20814
(Address Of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, Including Area Code (240) 497-9024

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

1
 

Item 8.01 Other Events.

 

On May 23, 2013, Northwest Biotherapeutics, Inc. (the “Company”) issued a press release announcing that it will use its exhibit at this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago to highlight its leadership role in immune therapy. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information disclosed under this Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No. Description

 

99.1 Press Release of Northwest Biotherapeutics, Inc. dated May 23, 2013.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NORTHWEST BIOTHERAPEUTICS, INC
     
Dated: May 23, 2013 By: /s/ Linda Powers
    Name:  Linda Powers
    Title: Chief Executive Officer and Chairman
     

 

2